InCephalo Therapeutics is a preclinical stage biotech company developing local treatments for neurological diseases with a focus on cancers in the brain. The company's C-Lock or Compartment Lock technology retains biologics that are applied locally behind the blood-brain barrier in the central nervous system (CNS) and once they leave the CNS, degrade rapidly in the systemic compartment. Thereby, it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects).
